Regeneron stock: Piper Sandler raises target to USD 865.00

Published on 10/21/2026 at 17:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year. Regeneron stock costs EUR 714.45 on October 21, 2026.

Analyst target and earnings

Piper Sandler raised its Regeneron target from USD 854.00 to USD 865.00 on October 19, 2026.
Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
Regeneron stock costs EUR 714.45 at Lang & Schwarz on October 21, 2026 at 5:40 p.m. CEST.
The company reported adjusted earnings per share of USD 14.29 for the second quarter of 2026.

Schwarzweiß-Dokumentarfoto einer Wissenschaftlerin bei der Laborarbeit mit Pipette — Regeneron Pharma US75886F1075 illustriert eine dokumentarische Schwarzweiß-Reportage einer Wissenschaftlerin bei konzentrierter Antikörper-Laborarbeit im Forschungsraum, Illustration mit AI erstellt.

Regeneron Pharmaceuticals (ISIN US75886F1075) received a higher USD 865.00 price target from Piper Sandler on October 19, 2026, up from USD 854.00. According to MarketBeat, the firm maintained an overweight rating. The target stands 7.89 percent above the USD 801.73 Nasdaq quotation used for the calculation. At Lang & Schwarz, the stock was trading at EUR 714.45 on October 21, 2026 at 5:40 p.m. CEST.

Revenue reached USD 4.29 billion

Regeneron reported USD 4.29 billion in revenue for the second quarter of 2026, an increase of 16.70 percent from the same quarter a year earlier. The company also reported adjusted earnings per share of USD 14.29, compared with analyst expectations of USD 10.16 for that period, according to MarketBeat.

Stock stays below its yearly high

Regeneron traded at USD 801.73 on Nasdaq at 11:42 a.m. ET on October 21, 2026. Its 52-week range was USD 572.75 to USD 859.34, while market capitalization stood at USD 82.5 billion on the same date. The latest quotation was 6.70 percent below the 52-week high.

Valuation and company profile

The company had a trailing P/E ratio of 19.83 on October 21, 2026. Regeneron describes its pipeline as having nearly 50 candidates in development and 16 approved medicines developed in-house on its corporate website, which also identifies research and development as the foundation of its business. The company operates in biotechnology and develops treatments for serious diseases.

For investors, the contrast is clear: the latest target revision points to USD 865.00, while the current Nasdaq quotation remains below that level. The second-quarter revenue increase provides a separate operating measure, but the next valuation signal will depend on how the pipeline develops alongside established products.

Price and target in perspective

The Piper Sandler target of USD 865.00 is 7.89 percent above the USD 801.73 Nasdaq quotation on October 21, 2026. Regeneron's current EUR 714.45 Lang & Schwarz price gives German investors a separate euro trading reference for the same company.

Regeneron was trading at EUR 714.45 at Lang & Schwarz on October 21, 2026 at 5:40 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.